Home » Stocks » MRKR

Marker Therapeutics, Inc. (MRKR)

Stock Price: $1.72 USD -0.03 (-1.71%)
Updated December 2, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 82.60M
Revenue (ttm) 679,979
Net Income (ttm) -25.28M
Shares Out 46.87M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $1.72
Previous Close $1.75
Change ($) -0.03
Change (%) -1.71%
Day's Open 1.74
Day's Range 1.67 - 1.75
Day's Volume 98,352
52-Week Range 1.36 - 3.35

More Stats

Market Cap 82.60M
Enterprise Value 67.87M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 46.87M
Float n/a
EPS (basic) -0.55
EPS (diluted) -0.55
FCF / Share -0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.63M
Short Ratio 24.15
Short % of Float n/a
Beta 1.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 121.48
PB Ratio 2.75
Revenue 679,979
Operating Income -25.74M
Net Income -25.28M
Free Cash Flow -24.26M
Net Cash 14.73M
Net Cash / Share 0.31
Gross Margin -1,845.88%
Operating Margin -3,785.32%
Profit Margin -3,717.50%
FCF Margin -3,567.31%
ROA -32.18%
ROE -64.42%
ROIC -204.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(306.98% upside)
Current: $1.72
Target: 7.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth3.5%12.53%------
Gross Profit0.210.210.18-----
Operating Income-22.53-148-11.48-8.49-6.16-3.37-2.66-5.48
Net Income-21.43-148-10.98-2.46-34.07-30.88-5.53-6.17
Shares Outstanding45.5919.099.456.893.661.290.090.05
Earnings Per Share-0.47-7.75-1.16-0.72-9.30-24.00-58.44-113.05
Operating Cash Flow-18.28-14.48-8.44-6.51-4.34-2.19-0.69-1.59
Capital Expenditures-0.37-0.15------
Free Cash Flow-18.66-14.63-8.44-6.51-4.34-2.19-0.69-1.59
Cash & Equivalents43.9061.755.137.856.580.140.050.03
Total Debt0.48--
Net Cash / Debt43.4261.755.137.856.520.09-3.43-1.52
Book Value44.0959.343.666.18-21.36-1.02-8.77-6.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Marker Therapeutics, Inc.
Country United States
Employees 28
CEO Peter Hoang

Stock Information

Ticker Symbol MRKR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRKR


Marker Therapeutics, a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.